Trial Profile
A Phase I, Single Dose, Single-centre, Randomized, Double-blind, Placebo-controlled Dose Escalation Study Evaluating Safety, Tolerability and Levodopa Plasma Concentration Following Administration of Subcutaneous Continuously-delivered Levodopa/Carbidopa Solution (ND0612) in Healthy Volunteers
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 23 Jan 2024
Price :
$35
*
At a glance
- Drugs Levodopa/carbidopa (Primary)
- Indications Parkinson's disease
- Focus Adverse reactions
- Sponsors NeuroDerm
- 16 Jun 2018 Results of this and another phase I/II study were presented at the 4th Congress of the European Academy of Neurology.
- 20 Jun 2013 Results presented at the 17th International Congress of Parkinson's Disease and Movement Disorders.
- 19 Jun 2013 Results presentated at the 17th International Congress of Parkinson's Disease and Movement Disorders, according to a NeuroDerm media release